Yes K, One of the masterstrokes of the immutep acquisition was retaining Treibel and
his commitment and knowledge, basically the hardest of the hard work was done before
we forked out $28M to buy it.....Researching immunology etc the current theme is
mix and match both by practical and technology means...As I have said before, we
are in the right place at the right time. hopefully us good guys get something out
of it.......By the way, Triebel has some 10M shares......Chairman and CSO both
heavily invested, take out of that what you will....
Ann: Prima unveils Phase I combination study of IMP321, page-8
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.0¢ | 31.0¢ | $306.8K | 972.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 178587 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 44597 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |